1. Home
  2. MLYS vs NRC Comparison

MLYS vs NRC Comparison

Compare MLYS & NRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • NRC
  • Stock Information
  • Founded
  • MLYS 2019
  • NRC 1981
  • Country
  • MLYS United States
  • NRC United States
  • Employees
  • MLYS N/A
  • NRC N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • NRC Biotechnology: Commercial Physical & Biological Resarch
  • Sector
  • MLYS Health Care
  • NRC Health Care
  • Exchange
  • MLYS Nasdaq
  • NRC Nasdaq
  • Market Cap
  • MLYS 590.3M
  • NRC 519.9M
  • IPO Year
  • MLYS 2023
  • NRC N/A
  • Fundamental
  • Price
  • MLYS $13.88
  • NRC $19.97
  • Analyst Decision
  • MLYS Strong Buy
  • NRC
  • Analyst Count
  • MLYS 2
  • NRC 0
  • Target Price
  • MLYS $30.00
  • NRC N/A
  • AVG Volume (30 Days)
  • MLYS 122.0K
  • NRC 65.7K
  • Earning Date
  • MLYS 11-05-2024
  • NRC 11-05-2024
  • Dividend Yield
  • MLYS N/A
  • NRC 2.41%
  • EPS Growth
  • MLYS N/A
  • NRC 1.10
  • EPS
  • MLYS N/A
  • NRC 1.19
  • Revenue
  • MLYS N/A
  • NRC $146,280,000.00
  • Revenue This Year
  • MLYS N/A
  • NRC N/A
  • Revenue Next Year
  • MLYS N/A
  • NRC N/A
  • P/E Ratio
  • MLYS N/A
  • NRC $16.98
  • Revenue Growth
  • MLYS N/A
  • NRC N/A
  • 52 Week Low
  • MLYS $5.85
  • NRC $19.92
  • 52 Week High
  • MLYS $16.91
  • NRC $46.84
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 70.82
  • NRC 33.99
  • Support Level
  • MLYS $11.73
  • NRC $21.50
  • Resistance Level
  • MLYS $12.27
  • NRC $22.99
  • Average True Range (ATR)
  • MLYS 0.61
  • NRC 0.70
  • MACD
  • MLYS 0.19
  • NRC -0.18
  • Stochastic Oscillator
  • MLYS 98.50
  • NRC 1.68

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About NRC National Research Corporation (Delaware)

National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.

Share on Social Networks: